Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trialLaurent Peyrin‐Biroulet, Peter Bossuyt, Pascal Juillerat et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 96
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Remo Panaccione, Flávio Steinwurz et al.|Gastroenterology|2025Cited by 46
Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn’s DiseaseFerdinando D’Amico, Silvio Danese, Sarah Bencardino et al.|Biologics|2025Cited by 5